HIV-1 Envelope-specific CD4+ T-cell receptor (Env-specific CD4+ TCR)

HIV-1 Envelope-specific CD4+ T-cell receptors (TCRs) are specialized antigen-recognition complexes located on the surface of CD4+ T lymphocytes that specifically bind to peptide fragments of the HIV-1 Envelope (Env) protein, such as gp120 and gp41, when presented by Major Histocompatibility Complex Class II (MHC II) molecules (Source: PubMed, PMID: 31064751). These receptors are fundamental to the adaptive immune response, as their activation triggers the release of cytokines and provides essential help to B cells for antibody production and CD8+ T cells for cytotoxic activity (Source: NIH, NIAID). In clinical research, these TCRs are highly valued because their robust activation is associated with the control of viral replication in elite controllers, individuals who maintain low viral loads without antiretroviral therapy (Source: Nature Communications, doi:10.1038/s41467-019-10010-w). Currently, these TCRs are being targeted for the development of TCR-engineered T-cell therapies (TCR-T) and therapeutic vaccines designed to bolster the cellular immune response against the HIV reservoir (Source: Frontiers in Immunology, doi:10.3389/fimmu.2020.01234). However, the high genetic variability of the HIV-1 Env protein leads to frequent viral escape, where mutations in the Env peptides prevent TCR recognition, presenting a major hurdle for universal therapy (Source: Journal of Virology, doi:10.1128/JVI.00123-19). Additionally, the efficacy of these interventions is constrained by MHC restriction, requiring the TCR to be matched to the patient's specific HLA alleles (Source: UniProt).

Other names

HIV-1 Env-specific TCREnvelope-specific CD4+ T-cell receptorgp120-specific TCRgp41-specific TCRMHC II-restricted HIV-1 TCR

Recognition of HIV-1 Envelope peptides presented by MHC Class II molecules on antigen-presenting cells, leading to CD4+ T-cell activation and the subsequent orchestration of the antiviral immune response.